NASDAQ:ABIO ARCA biopharma (ABIO) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ABIO Stock Alerts $3.72 +0.27 (+7.83%) (As of 02:39 PM ET) Add Compare Share Share Today's Range$3.45▼$3.7550-Day Range$1.60▼$3.4552-Week Range$1.56▼$3.88Volume161,718 shsAverage Volume1.15 million shsMarket Capitalization$53.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ARCA biopharma alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About ARCA biopharma Stock (NASDAQ:ABIO)ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.Read More ABIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABIO Stock News HeadlinesApril 20, 2024 | money.usnews.comARCA biopharma IncApril 20, 2024 | msn.com18-year-old Jake Finch leads every lap to capture ARCA victory at TalladegaApril 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 20, 2024 | americanbankingnews.comStockNews.com Begins Coverage on ARCA biopharma (NASDAQ:ABIO)April 16, 2024 | americanbankingnews.comARCA biopharma, Inc. (NASDAQ:ABIO) Short Interest Up 6.6% in MarchApril 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIOApril 5, 2024 | businesswire.comARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIOApril 3, 2024 | investorplace.comWhy Is ARCA Biopharma (ABIO) Stock Up 85% Today?April 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 3, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether ARCA biopharma, Inc. has obtained a Fair Price in its transaction with OrukaApril 3, 2024 | marketwatch.comARCA Biopharma in Reverse Merger Pact With Oruka TherapeuticsApril 3, 2024 | msn.comFibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare moversApril 3, 2024 | bizjournals.comNew Paragon spinout lands $275M financing — and reverse mergerApril 3, 2024 | markets.businessinsider.comARCA Biopharma, Oruka Therapeutics To Combine In All-stock Deal - Quick FactsApril 3, 2024 | msn.comSmall-Cap ARCA Biopharma Stock Soars On Merger Pact: The DetailsApril 3, 2024 | businesswire.comABIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ARCA Biopharma, Inc. Is Fair to ShareholdersApril 3, 2024 | globenewswire.comARCA biopharma and Oruka Therapeutics Announce Merger AgreementApril 3, 2024 | globenewswire.comARCA biopharma and Oruka Therapeutics Announce Merger AgreementMarch 27, 2024 | msn.comARCA Sensation Toni Breidinger Divulges Struggles of ‘Imposter’ Feeling in Male-Dominated NASCARMarch 19, 2024 | finance.yahoo.comRx Outreach builds first St. Louis community pharmacy in partnership with ARCA to rid barriers, promote healthMarch 15, 2024 | finance.yahoo.comABIO Apr 2024 2.500 callMarch 11, 2024 | msn.comARCA throws red flag for General Tire 150 at Phoenix due to lightningFebruary 23, 2024 | benzinga.comARCA biopharma Stock (NASDAQ:ABIO) Dividends: History, Yield and DatesFebruary 18, 2024 | msn.comGus Dean wins ARCA 200 at Daytona in overtime after teammate controversyFebruary 18, 2024 | msn.com“I Better Not Comment on That”- Marco Andretti Cites “New Guy” Claims as He Refuses to Call Out ARCA Stars Despite Daytona WreckfestFebruary 18, 2024 | msn.comARCA driver Andy Jankowiak delivers epic quote during Daytona raceFebruary 16, 2024 | news.yahoo.comDaytona 500: ARCA 200 race moved up to Friday due to inclement weatherSee More Headlines Receive ABIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/01/2024Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:ABIO CUSIPN/A CIK907654 Webarcabio.com Phone(720) 940-2100Fax720-208-9261Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-13.80% Return on Assets-13.33% Debt Debt-to-Equity RatioN/A Current Ratio59.01 Quick Ratio59.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book1.19Miscellaneous Outstanding Shares14,500,000Free Float10,020,000Market Cap$50.03 million OptionableOptionable Beta1.17 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Michael R. Bristow M.D. (Age 79)Ph.D., Co-Founder, President, CEO & Director Comp: $358.8kMr. C. Jeffrey Dekker CPA (Age 59)CFO, Treasurer & Company Secretary Comp: $323.07kMr. Thomas A. Keuer (Age 65)Chief Operating Officer Comp: $400.8kKey CompetitorsVolitionRxNYSE:VNRXAspira Women's HealthNASDAQ:AWHImmuCellNASDAQ:ICCCOncoCyteNASDAQ:OCXCardio DiagnosticsNASDAQ:CDIOView All CompetitorsInstitutional OwnershipCable Car Capital LLCBought 4,000,452 shares on 2/20/2024Ownership: 27.589%Simplex Trading LLCBought 500 shares on 2/2/2024Ownership: 0.000%abrdn plcBought 32,461 shares on 1/31/2024Ownership: 0.000%View All Institutional Transactions ABIO Stock Analysis - Frequently Asked Questions How have ABIO shares performed in 2024? ARCA biopharma's stock was trading at $1.70 at the beginning of 2024. Since then, ABIO shares have increased by 113.5% and is now trading at $3.63. View the best growth stocks for 2024 here. Are investors shorting ARCA biopharma? ARCA biopharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 195,700 shares, an increase of 6.6% from the March 15th total of 183,600 shares. Based on an average daily volume of 1,340,000 shares, the short-interest ratio is presently 0.1 days. Currently, 1.4% of the shares of the company are short sold. View ARCA biopharma's Short Interest. How were ARCA biopharma's earnings last quarter? ARCA biopharma, Inc. (NASDAQ:ABIO) issued its quarterly earnings data on Thursday, February, 1st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. What is Michael R. Bristow's approval rating as ARCA biopharma's CEO? 1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ARCA biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP). How do I buy shares of ARCA biopharma? Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABIO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARCA biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
